Literature DB >> 28367888

The First Case of Zika Virus Isolated from a Japanese Patient Who Returned to Japan from Fiji in 2016.

Masakatsu Taira1, Tomoko Ogawa1, Haruna Nishijima1, Kojiro Yamamoto2, Chiemi Hotta1, Mamiko Akita1, Shigeru Tajima3, Masayuki Saijo3.   

Abstract

Outbreaks of Zika virus (ZIKV) infection in tropical and subtropical regions are a cause of worldwide concern and represent a public health emergency. ZIKV was isolated from a 17-year-old patient with fever and maculopapular rash. The patient returned to Japan from the Republic of Fiji in late April 2016. The complete genome sequence of the ZIKV isolate (ZIKV/Hu/S36/Chiba/2016), which might be the first strain to be isolated in Japan, was identified and reported.

Entities:  

Keywords:  Japan; Zika virus; whole genome sequence

Mesh：

Year:  2017        PMID： 28367888     DOI： 10.7883/yoken.JJID.2017.042

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN： 1344-6304            Impact factor:   1.362


  3 in total

1.  Characterization of large and small-plaque variants in the Zika virus clinical isolate ZIKV/Hu/S36/Chiba/2016.

Authors:  Fumihiro Kato; Shigeru Tajima; Eri Nakayama; Yasuhiro Kawai; Satoshi Taniguchi; Kenichi Shibasaki; Masakatsu Taira; Takahiro Maeki; Chang Kweng Lim; Tomohiko Takasaki; Masayuki Saijo
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

2.  Increased growth ability and pathogenicity of American- and Pacific-subtype Zika virus (ZIKV) strains compared with a Southeast Asian-subtype ZIKV strain.

Authors:  Yasuhiro Kawai; Eri Nakayama; Kenta Takahashi; Satoshi Taniguchi; Ken-Ichi Shibasaki; Fumihiro Kato; Takahiro Maeki; Tadaki Suzuki; Shigeru Tajima; Masayuki Saijo; Chang-Kweng Lim
Journal:  PLoS Negl Trop Dis       Date:  2019-06-06

Review 3.  Probiotics and Paraprobiotics in Viral Infection: Clinical Application and Effects on the Innate and Acquired Immune Systems.

Authors:  Osamu Kanauchi; Akira Andoh; Sazaly AbuBakar; Naoki Yamamoto
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.